# Disease Severity- and Hormonal Status-Dependent Alterations of EGF and MIF in the Serum of Endometriosis Patients

**Authors:** Norbert Tóth, Réka Brubel, Attila Bokor, Ágnes Kemény, Nelli Farkas, Tibor Pál, Zsuzsanna Helyes, Krisztina Pohóczky

PMC · DOI: 10.3390/ijms26146695 · International Journal of Molecular Sciences · 2025-07-12

## TL;DR

The study finds that hormone levels and disease severity affect certain proteins in the blood of endometriosis patients, but these changes are not reliable for diagnosis.

## Contribution

The study identifies serum EGF and MIF as markers influenced by disease severity and hormonal status in endometriosis patients.

## Key findings

- Serum EGF levels are significantly lower in mild endometriosis and during the secretory phase.
- MIF and IL-6 levels are elevated in endometriosis patients across all disease stages.
- Serum EGF and somatostatin correlate with pain symptoms in mild endometriosis cases.

## Abstract

Endometriosis is the extrauterine engraftment of endometrium-like tissue, causing chronic pain. Complex sensory–vascular–immune interactions, including growth factors, cytokines, and neuropeptides, are implicated in its pathophysiology, but the mechanisms remain unknown. Here, epidermal growth factor (EGF), vascular endothelial growth factor, interleukins (IL-1β, IL-6, IL-8), macrophage migration inhibitory factor (MIF), calcitonin gene-related peptide, and somatostatin were measured in the serum of endometriosis patients with different disease severities, menstruation cycle- and pharmacotherapy-related hormonal status compared with controls. Mediator levels in deep-infiltrating rectosigmoid nodules were also compared with those in non-endometriotic colon tissues. Pain was assessed by the visual analogue scale. Serum EGF was significantly lower in mild endometriosis and in the secretory phase. MIF and IL-6 were higher in stage I–IV endometriosis, with MIF also higher in the secretory phase and in patients not receiving oral contraceptives. Somatostatin was lower in mild endometriosis than that in healthy individuals and the severe endometriosis group. No tissue-level differences were found. A strong positive correlation between serum EGF and somatostatin levels and dysmenorrhea and dysuria was detected in mild cases. It is concluded that certain serum alterations may be related to severity- and hormone status-dependent endometriosis mechanisms, but their diagnostic/prognostic value seems to be limited due to variability and lack of specificity.

## Linked entities

- **Proteins:** EGF (epidermal growth factor), IL1B (interleukin 1 beta), IL6 (interleukin 6), CXCL8 (C-X-C motif chemokine ligand 8), MIF (macrophage migration inhibitory factor)
- **Diseases:** endometriosis (MONDO:0005133)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SST (somatostatin) [NCBI Gene 6750] {aka SMST, SST1}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, MIF (macrophage migration inhibitory factor) [NCBI Gene 4282] {aka GIF, GLIF, MMIF}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}
- **Diseases:** dysmenorrhea (MESH:D004412), Endometriosis (MESH:D004715), chronic pain (MESH:D059350), I-IV (MESH:D006011), Pain (MESH:D010146), dysuria (MESH:D053159)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12294931/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12294931/full.md

## References

79 references — full list in the complete paper: https://tomesphere.com/paper/PMC12294931/full.md

---
Source: https://tomesphere.com/paper/PMC12294931